Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1959 2
1961 2
1962 1
1963 2
1964 2
1965 6
1966 1
1967 6
1968 1
1969 11
1970 5
1971 8
1972 2
1973 8
1974 9
1975 5
1976 9
1977 6
1978 12
1979 10
1980 16
1981 11
1982 21
1983 10
1984 13
1985 18
1986 28
1987 18
1988 25
1989 29
1990 18
1991 22
1992 30
1993 32
1994 35
1995 48
1996 51
1997 51
1998 54
1999 48
2000 48
2001 58
2002 63
2003 50
2004 53
2005 58
2006 64
2007 60
2008 72
2009 79
2010 96
2011 119
2012 105
2013 100
2014 111
2015 112
2016 101
2017 125
2018 112
2019 159
2020 129
2021 137
2022 143
2023 124
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

2,736 results

Results by year

Filters applied: . Clear all
Page 1
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M; NEURO-TTRansform Investigators. Coelho T, et al. Among authors: ando y. JAMA. 2023 Oct 17;330(15):1448-1458. doi: 10.1001/jama.2023.18688. JAMA. 2023. PMID: 37768671
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis.
Ando Y, Adams D, Benson MD, Berk JL, Planté-Bordeneuve V, Coelho T, Conceição I, Ericzon BG, Obici L, Rapezzi C, Sekijima Y, Ueda M, Palladini G, Merlini G. Ando Y, et al. Amyloid. 2022 Sep;29(3):143-155. doi: 10.1080/13506129.2022.2052838. Epub 2022 Jun 2. Amyloid. 2022. PMID: 35652823
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM. Dorbala S, et al. Among authors: ando y. Circ Cardiovasc Imaging. 2021 Jul;14(7):e000029. doi: 10.1161/HCI.0000000000000029. Epub 2021 Jul 1. Circ Cardiovasc Imaging. 2021. PMID: 34196223 Free article. Review. No abstract available.
[RANKL and periodontitis].
Ando Y, Tsukasaki M. Ando Y, et al. Nihon Yakurigaku Zasshi. 2023;158(3):263-268. doi: 10.1254/fpj.22122. Nihon Yakurigaku Zasshi. 2023. PMID: 37121710 Review. Japanese.
Modified uvsY by N-terminal hexahistidine tag addition enhances efficiency of recombinase polymerase amplification to detect SARS-CoV-2 DNA.
Juma KM, Takita T, Yamagata M, Ishitani M, Hayashi K, Kojima K, Suzuki K, Ando Y, Fukuda W, Fujiwara S, Nakura Y, Yanagihara I, Yasukawa K. Juma KM, et al. Among authors: ando y. Mol Biol Rep. 2022 Apr;49(4):2847-2856. doi: 10.1007/s11033-021-07098-y. Epub 2022 Jan 31. Mol Biol Rep. 2022. PMID: 35098395 Free PMC article.
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events.
Schöffski P, Concin N, Suarez C, Subbiah V, Ando Y, Ruan S, Wagner JP, Mansfield K, Zhu X, Origuchi S, DiDominick S, Bialucha CU, Faris JE, Tran B. Schöffski P, et al. Among authors: ando y. Oncol Res Treat. 2021;44(10):547-556. doi: 10.1159/000518549. Epub 2021 Aug 19. Oncol Res Treat. 2021. PMID: 34515215 Free article. Clinical Trial.
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T, Waddington Cruz M, Chao CC, Parman Y, Wixner J, Weiler M, Barroso FA, Dasgupta NR, Jung SW, Schneider E, Viney NJ, Dyck PJB, Ando Y, Gillmore JD, Khella S, Gertz MA, Obici L, Berk JL. Coelho T, et al. Among authors: ando y. Neurol Ther. 2023 Feb;12(1):267-287. doi: 10.1007/s40120-022-00414-z. Epub 2022 Dec 16. Neurol Ther. 2023. PMID: 36525140 Free PMC article.
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.
Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Coelho T, et al. Among authors: ando y. Neurol Ther. 2021 Jun;10(1):375-389. doi: 10.1007/s40120-021-00235-6. Epub 2021 Feb 26. Neurol Ther. 2021. PMID: 33638113 Free PMC article.
2,736 results